CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

GlobeNewswire•November 14, 2019 OXNARD, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents…